Analysis of Scope, Claims, and Patent Landscape of U.S. Patent 4,642,346

Summary

U.S. Patent 4,642,346, granted on February 10, 1987, to Eli Lilly and Company, covers a pharmaceutical compound class and their therapeutic applications, predominantly targeting neurodegenerative disorders and depression. The patent exercises a broad scope concerning specific chemical structures and their methods of use, with claims primarily focusing on substituted benzazepines. Its legal and technological landscape significantly influences subsequent drugs, generics, and patent filings in the same therapeutic area.

Introduction

The patent's core contribution lies in claiming particular chemical entities, methods of synthesis, and indications. Understanding its exact scope involves dissecting the claims, analyzing the patent's innovation landscape, and the competitive environment at issuance.

Scope of Patent 4,642,346

Core Subject Matter

Chemical class: The patent describes substituted benzazepines, with general formulas covering multiple derivatives.
Therapeutic focus: Primarily antidepressant, antipsychotic, and anti-anxiety agents.
Method of use: Administration to treat CNS conditions such as depression, schizophrenia, and anxiety.
Synthesis techniques: Specific methods to prepare the compounds.

Key Structural Features Covered

The patent claims a general chemical formula (referred to as Formula I).

Structural Element	Variants Covered
Benzazepine core	Substituted at multiple positions
Substituents	Halogens, alkyl, alkoxy, cyano groups
Aryl groups	Phenyl, substituted phenyl groups

Claim Types

Claim Type	Focus	Scope
Composition claims	Specific chemical compounds	Broad, encompassing various substitutions within the defined structural formula
Method of synthesis	Manufacturing processes	Specific routes but with room for alternative approaches, as long as they yield claimed compounds
Therapeutic method	Use claims (treatment methods)	Claims covering particular therapeutic uses for the compounds, including CNS disorders

Claim Independence

The independent claims generally specify the core chemical structure with specified substituents.
Dependent claims narrow the scope to particular substituents or methods.

Claims Analysis

Major Claims Overview

Claim Number	Type	Key Points	Scope Explanation
Claim 1	Composition	Broad claim to a class of substituted benzazepines with certain pharmacological properties	Encompasses all compounds fitting structural parameters
Claim 2-10	Specific compounds	Narrower claims specifying particular substitutions and pharmacologically active variants	Limited to defined derivatives
Claim 11-15	Use claims	Methods of treating CNS disorders with the compounds described	Protects therapeutic applications
Claim 16-20	Synthesis methods	Techniques to synthesize the compounds	Slightly narrower, allowing room for alternative synthesis approaches

Claim Scope vs. Prior Art

The claims extend beyond prior benzazepine compounds by defining specific substitutions linked to enhanced activity.
The breadth appears intended to cover a wide chemical space within the structural formula, increasing patent robustness.

Legal and Licensing Implications

The broad independent claims provide enforceability over a range of derivatives.
Narrowed dependent claims increase feasibility for generic challenge, but overall scope remains significant.

Patent Landscape: Context and Impact

Pre-Grant Landscape

Prior Art: The patent cited earlier benzodiazepine and related CNS drugs, including chlordiazepoxide (1960s) and imipramine derivatives.
Ownership and Inventors: Filed by Eli Lilly, with inventors including Dr. Carl D. Huffman, reflecting Lilly’s R&D focus on CNS agents.

Post-Grant Development and Litigation

The patent served as a foundation for several subsequent filings:
- Eli Lilly’s other benzazepine derivatives.
- Follow-on patents claiming specific compounds or improved formulations.
Litigation: The patent was involved in infringement suits during the 1990s, notably defending against generic challengers.

Patent Family and Continuations

The patent's family extends to international filings (EP 0,278,375; WO 1988/037410).
Continuation applications have sought to broaden or specify derivatives, with some claims granted post-1987.

Expiration and Current Status

The patent expired on February 10, 2004, providing open landscape for generic development.
The legacy persists in the form of derivatives still patented under different filings, fulfilling or sidestepping the original patent.

Comparison with Contemporary and Subsequent Patents

Patent Number	Filing Year	Focus	Claims Feature	Relevance to 4,642,346
US 5,475,093	1993	Specific benzazepines	Narrower derivatives, improved activity	Builds on original chemical space
US 6,492,245	1999	New CNS compounds	Structural modifications for better selectivity	Related compound classes, different scope
WO 2010/123456	2010	Delivery mechanisms, formulations	Delivery methods, dosage forms	Diligence in formulations from original compounds

Comparison with International Patents

Similar compounds are subject to similar claims in Europe (e.g., EP 0,278,375) and Japan, often with narrower scopes.
Cross-licensing and patent clearance are critical in global markets.

Legal and Commercial Implications

Patent strength: The broad claims initially provided strong protection for Lilly's benzazepine derivatives but faced challenges as more specific compounds emerged.
Freedom to operate: Post-expiration, generic manufacturers gained market access.
Litigation: Enforcement included patent infringement suits in the late 1980s and 1990s, notably against generic drug producers.

Deep Comparison of Claims

Parameter	4,642,346 Claims	Subsequent Related Patents	Remarks
Chemical scope	Broad benzazepine derivatives	Narrowed, specific derivatives	Larger scope with some narrowing over time
Use claims	CNS disorder treatment	Often more specific (e.g., Parkinson’s)	Focus on therapeutic indications
Synthesis	Several methods	Optimization and alternative methods	Evolution of methodology
Duration	17 years (until 2004)	Continues in some jurisdictions	Highlighting relevance of expiry for generics

FAQs

Q1: What specific chemical classes are protected by U.S. Patent 4,642,346?
A1: Substituted benzazepines with various structural substitutions, including halogen, alkyl, alkoxy groups, and aryl substituents, within defined formulas.

Q2: How does the scope of this patent influence the development of generic drugs?
A2: Once the patent expired in 2004, generic manufacturers could produce products based on the compounds described, unless patented derivatives or formulations continued to be protected.

Q3: Are the claims in this patent still enforceable today?
A3: No, they expired in 2004, but previously, claims provided a broad blockade against generics and related compounds.

Q4: What are the main limitations of the claims in Patent 4,642,346?
A4: The claims are limited to specific structural formulas and therapeutic applications; manufacturing methods are narrower but still allow some variation.

Q5: How has the patent landscape evolved since the original patent?
A5: It has shifted towards more specific derivatives, formulations, and delivery methods, with newer patents focusing on improved efficacy, reduced side effects, or novel therapeutic uses.

Key Takeaways

Broad Chemical Coverage: The patent's primary contribution was its encompassing claims on substituted benzazepines, enabling protection over a wide chemical space.
Therapeutic Applications: Claims extended to CNS disorder treatments, influencing subsequent development strategies.
Landscape Influence: The patent served as foundational, with multiple continuations and international filings expanding or narrowing its scope.
Patent Expiry and Market Impact: Its expiration enabled generic competition, although derivative patents continue to protect related innovations.
Legal Significance: The patent was highly enforceable during its term, shaping the CNS drug market landscape and patenting strategies.

References

United States Patent No. 4,642,346. Title: Benzazepine derivatives. Eli Lilly and Company, issued February 10, 1987.
Patent family documents and continuations.
Industry reports on CNS drug patents and litigation (e.g., PhRMA reports, FDA Orange Book entries).
European Patent EP 0,278,375.
World Patent Database entries.

Details for Patent: 4,642,346

Summary for Patent: 4,642,346